Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 147.34 billion. The enterprise value is 144.04 billion.

Market Cap	147.34B
Enterprise Value	144.04B

Important Dates

The last earnings date was Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	Sep 3, 2025

Share Statistics

Current Share Class	104.62M
Shares Outstanding	n/a
Shares Change (YoY)	+0.27%
Shares Change (QoQ)	+0.76%
Owned by Insiders (%)	61.09%
Owned by Institutions (%)	14.34%
Float	26.39M

Valuation Ratios

The trailing PE ratio is 45.48 and the forward PE ratio is 32.94.

PE Ratio	45.48
Forward PE	32.94
PS Ratio	13.10
PB Ratio	8.07
P/TBV Ratio	8.07
P/FCF Ratio	113.62
P/OCF Ratio	60.25
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 31.98, with an EV/FCF ratio of 111.08.

EV / Earnings	44.46
EV / Sales	12.80
EV / EBITDA	31.98
EV / EBIT	37.27
EV / FCF	111.08

Financial Position

The company has a current ratio of 6.97, with a Debt / Equity ratio of 0.00.

Current Ratio	6.97
Quick Ratio	4.70
Debt / Equity	0.00
Debt / EBITDA	0.00
Debt / FCF	0.01
Interest Coverage	1,231.03

Financial Efficiency

Return on equity (ROE) is 18.93% and return on invested capital (ROIC) is 13.97%.

Return on Equity (ROE)	18.93%
Return on Assets (ROA)	12.62%
Return on Invested Capital (ROIC)	13.97%
Return on Capital Employed (ROCE)	20.47%
Revenue Per Employee	7.16M
Profits Per Employee	2.06M
Employee Count	1,571
Asset Turnover	0.59
Inventory Turnover	1.53

Taxes

In the past 12 months, Concord Biotech has paid 1.06 billion in taxes.

Income Tax	1.06B
Effective Tax Rate	24.63%

Stock Price Statistics

The stock price has decreased by -35.57% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-35.57%
50-Day Moving Average	1,495.21
200-Day Moving Average	1,655.69
Relative Strength Index (RSI)	38.83
Average Volume (20 Days)	2,932

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 11.25 billion and earned 3.24 billion in profits. Earnings per share was 30.89.

Revenue	11.25B
Gross Profit	7.22B
Operating Income	3.82B
Pretax Income	4.29B
Net Income	3.24B
EBITDA	4.45B
EBIT	3.82B
Earnings Per Share (EPS)	30.89

Full Income Statement

Balance Sheet

The company has 3.31 billion in cash and 16.07 million in debt, giving a net cash position of 3.30 billion.

Cash & Cash Equivalents	3.31B
Total Debt	16.07M
Net Cash	3.30B
Net Cash Per Share	n/a
Equity (Book Value)	18.27B
Book Value Per Share	173.32
Working Capital	9.25B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.45 billion and capital expenditures -1.15 billion, giving a free cash flow of 1.30 billion.

Operating Cash Flow	2.45B
Capital Expenditures	-1.15B
Free Cash Flow	1.30B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 64.20%, with operating and profit margins of 33.98% and 28.79%.

Gross Margin	64.20%
Operating Margin	33.98%
Pretax Margin	38.14%
Profit Margin	28.79%
EBITDA Margin	39.52%
EBIT Margin	33.98%
FCF Margin	11.53%

Dividends & Yields

This stock pays an annual dividend of 10.70, which amounts to a dividend yield of 0.76%.

Dividend Per Share	10.70
Dividend Yield	0.76%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	34.55%
Buyback Yield	-0.27%
Shareholder Yield	0.50%
Earnings Yield	2.20%
FCF Yield	0.88%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	4